Agencies cooperate in ensuring safe use of antineoplastic agents
Ashwin, J.
Canadian Medical Association Journal 128(8): 907-908
1983
ISSN/ISBN: 0008-4409 PMID: 6831335 Document Number: 217617
Document emailed within 1 workday
Related Documents
Tokutome, A.; Taniguchi, R.; Maeda, K.; Saito, Y.; Ishii, T.; Minami, S.; Wano, Y.; Ota, T.; Saitoh, H.; Takeda, K. 2018: The Usefulness of a Pamphlet for Preventing Exposure to Antineoplastic Agents at Cancer Patients' Homes and an Awareness Survey for Pharmacists about Providing Information to Cancer Patients about Exposure to Antineoplastic Agents Gan to Kagaku Ryoho. Cancer and ChemoTherapy 45(5): 833-839Tansley, K.; Gray, J. 2009: Ensuring safe and appropriate discharge for people who are homeless or in housing need Nursing Times 105(40): 14-17
Mixon, B.; Ille, G. 2009: Preventing nonmicrobiologic airborne contamination in the compounding pharmacy: ensuring a safe environment for compounders, staff, and clients International Journal of Pharmaceutical Compounding 13(4): 290-294
Zimmerman, P.F.; Larsen, R.K.; Barkley, E.W.; Gallelli, J.F. 1981: Recommendations for the safe handling of injectable antineoplastic drug products American Journal of Hospital Pharmacy 38(11): 1693-1695
Maitra, A 2008: Ensuring Safe Motherhood by Using Information and Communication Technology Tools in Behavioral Change Communication Marriage and Family Review 44(2-3): 350-356
Shigeoka, Y.; Shimizu, E. 2007: Myelosuppression due to antineoplastic agents Nihon Rinsho. Japanese Journal of Clinical Medicine 65(Suppl 8): 287-293
Aiello, E.; Dattolo, G.; Cirrincione, G.; Almerico, A.M.; Diana, P.; Grimaudo, S.; Mingoia, F.; Barraja, P. 1995: Azolophenanthridines as antineoplastic agents Farmaco 50(6): 365-368
1971: Chemistry of antineoplastic agents Minerva Medica 62(28): 1492
Mitolo-chieppa, D.; Ceci, A. 1974: Neurotoxicity of some antineoplastic agents Bollettino della Societa Italiana di Biologia Sperimentale 50(17): 1333-1359
Pettit, G.R.; Srirangam, J.K.; Barkoczy, J.; Williams, M.D.; Boyd, M.R.; Hamel, E.; Pettit, R.K.; Hogan, F.; Bai, R.; Chapuis, J.C.; McAllister, S.C.; Schmidt, J.M. 1998: Antineoplastic agents 365. Dolastatin 10 SAR probes Anti-Cancer Drug Design 13(4): 243-277
Wada, T.; Matsui, H. 2013: Research development of novel antineoplastic agents Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 142(4): 149
Berti, T. 1970: Specific histotropism of antineoplastic agents La Clinica Terapeutica 55(4): 293-303
Katz, L.M.; Donnelly, J.J.; Gresens, C.J.; Holmberg, J.A.; MacPherson, J.; Zacharias, P.J.K.; Stanley, J.; Bales, C. 2018: Report of a workshop on ensuring sustainable access to safe blood in developing countries: International Blood Safety Forum, March 24, 2017 Transfusion 58(5): 1299-1306
Katz, L.M.; Donnelly, J.J.; Gresens, C.J.; Holmberg, J.A.; MacPherson, J.; Zacharias, P.J.K.; Stanley, J.; Bales, C. 2018: Report of a workshop on ensuring sustainable access to safe blood in developing countries: International Blood Safety Forum, March 24, 2017 Transfusion 58(5): 1299-1306
Sakurai, Y. 1975: Deveolpment of new antineoplastic agents and their clinical characteristics Nihon Rinsho. Japanese Journal of Clinical Medicine 33(5): 1892-1896
Babaian, I.S.; Khudaverdian, N.V.; Karapetian, L.G.; Kazarian, R.S.; Sogomonian, L.R. 1997: Comparative study of three antineoplastic alkylating agents on DNA Biofizika 42(2): 542-543
Kato, T.; Nemoto, R. 1982: Clinical application of microencapsulated antineoplastic agents Nihon Rinsho. Japanese Journal of Clinical Medicine 40(2): 478-488
Le Guern, M. 1987: DNA-topoisomerase II: Cellular targets of antineoplastic agents Pathologie-Biologie 35(4): 343-345
Orfi, L.; Wáczek, F.; Szabó, M.; Kövesdi, I.; Mészáros, G.; Idei, M.; Horváth, A.; Hollósy, F.; Mák, M.; Szegedi, Z.; Szende, B.; Kéri, G.; Noszál, B. 1999: Preparation and characterization of potential antineoplastic agents Acta Pharmaceutica Hungarica 69(3): 115-122
Schmoll, H.J.; Hiddemann, W.; Rustum, Y.; Köhne-Wömpner, C.H. 1992: The emerging role for biomodulation of antineoplastic agents Seminars in Oncology 19(2 Suppl 3: 1-3